DOCSLIB.ORG

Giapreza 4930

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Giapreza 4930 27 June 2019 EMA/508753/2019 Committee for Medicinal Products for Human Use (CHMP) Assessment report Giapreza International non-proprietary name: angiotensin II Procedure No. EMEA/H/C/004930/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Administrative information Name of the medicinal product: Giapreza Applicant: La Jolla Pharmaceutical II B.V. Herengracht 500 1017 CB Amsterdam NETHERLANDS Active substance: Angiotensin II acetate International Non-proprietary Name/Common Angiotensin II Name: Pharmaco-therapeutic group Cardiac therapy, other cardiac stimulants (ATC Code): (C01CX09) Therapeutic indication(s): Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. Pharmaceutical form(s): Concentrate for solution for infusion Strength(s): 2.5 mg/ml Route(s) of administration: Intravenous use Packaging: vial (glass) Package size(s): 1 vial (1ml) and 1 vial (2 ml) Assessment report EMA/508753/2019 Page 2/139 Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion .............................................................................. 10 2.1. Problem statement ............................................................................................. 10 2.1.1. Disease or condition ........................................................................................ 10 2.1.2. Epidemiology .................................................................................................. 10 2.1.3. Biologic features .............................................................................................. 11 2.1.4. Clinical presentation, diagnosis .......................................................................... 11 2.1.5. Management ................................................................................................... 12 2.2. Quality aspects .................................................................................................. 15 2.2.1. Introduction.................................................................................................... 15 2.2.2. Finished medicinal product ................................................................................ 21 2.2.3. Discussion on chemical, and pharmaceutical aspects ............................................ 27 2.2.4. Conclusions on the chemical, pharmaceutical and biological aspects ....................... 27 2.2.5. Recommendations for future quality development ................................................ 27 2.3. Non-clinical aspects ............................................................................................ 28 2.3.1. Introduction.................................................................................................... 28 2.3.2. Pharmacology ................................................................................................. 29 2.3.3. Pharmacokinetics ............................................................................................ 31 2.3.4. Toxicology ...................................................................................................... 32 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 34 2.3.6. Discussion on non-clinical aspects ..................................................................... 35 2.3.7. Conclusion on the non-clinical aspects ................................................................ 35 2.4. Clinical aspects .................................................................................................. 35 2.4.1. Introduction.................................................................................................... 35 2.4.2. Pharmacokinetics ............................................................................................ 37 2.4.3. Pharmacodynamics .......................................................................................... 40 2.4.4. Discussion on clinical pharmacology ................................................................... 43 2.4.5. Conclusions on clinical pharmacology ................................................................. 45 2.5. Clinical efficacy .................................................................................................. 46 2.5.1. Dose response study(ies) ................................................................................. 46 2.5.2. Main study...................................................................................................... 46 2.5.3. Discussion on clinical efficacy ............................................................................ 78 2.5.4. Conclusions on the clinical efficacy ..................................................................... 90 2.6. Clinical safety .................................................................................................... 91 2.6.1. Discussion on clinical safety ............................................................................ 113 2.6.2. Conclusions on the clinical safety ..................................................................... 119 2.7. Risk Management Plan ...................................................................................... 120 2.8. Pharmacovigilance ........................................................................................... 123 2.9. New Active Substance ....................................................................................... 123 Assessment report EMA/508753/2019 Page 3/139 2.10. Product information ........................................................................................ 124 2.10.1. User consultation ......................................................................................... 124 2.10.2. Additional monitoring ................................................................................... 124 3. Benefit-Risk Balance ........................................................................... 124 3.1. Therapeutic Context ......................................................................................... 124 3.1.1. Disease or condition ...................................................................................... 124 3.1.2. Available therapies and unmet medical need ..................................................... 125 3.1.3. Main clinical studies ....................................................................................... 126 3.2. Favourable effects ............................................................................................ 126 3.3. Uncertainties and limitations about favourable effects ........................................... 128 3.4. Unfavourable effects ......................................................................................... 131 3.5. Uncertainties and limitations about unfavourable effects ....................................... 133 3.6. Effects Table .................................................................................................... 134 3.7. Benefit-risk assessment and discussion ............................................................... 135 3.7.1. Importance of favourable and unfavourable effects ............................................ 135 3.7.2. Balance of benefits and risks ........................................................................... 136 3.7.3. Additional considerations on the benefit-risk balance .......................................... 137 3.8. Conclusions ..................................................................................................... 137 4. Recommendations ............................................................................... 138 Assessment report EMA/508753/2019 Page 4/139 List of abbreviations DMF Dimethylformamide ESI-MS Electrospray Ionization Mass Spectrometry Fmoc fluorenyl-methyloxycarbonyl GC Gas Chromatography HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use IPC In-process control MAA Marketing Authorisation Application NMT Not more than PDE Permitted Daily Exposure Ph. Eur. European Pharmacopoeia PTFE Polytetrafluoroethylene RP Reverse Phase SPPS Solid Phase Peptide Synthesis SmPC Summary of Product Characteristics TAMC Total Aerobic Microbial Count TFA Trifluoroacetic acid TYMC Total Combined Yeasts/Moulds Count uHPLC ultra-high performance liquid chromatography XR(P)D X-Ray (Powder) Diffraction ACE: angiotensin-converting enzyme ACEi: angiotensin-converting enzyme inhibitor AE: adverse event AESI: adverse event of special interest ALT: alanine aminotransferase APACHE II: Acute Physiologic
Load more

Recommended publications
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 30 March 2021 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 30 March 2021 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • Amlodipine Besilate/Ancrod 1215
    Amlodipine Besilate/Ancrod 1215 Amosulalol Hydrochloride (rINNM) ⊗ The adverse effects associated with oral use have made dose may be repeated after 30 minutes if necessary. Amosulalol, Chlorhydrate d’; Amosulaloli Hydrochloridum; Hid- this route unacceptable and amrinone is now only giv- Maintenance doses are 5 to 10 micrograms/kg per rocloruro de amosulalol; YM-09538. (±)-5-(1-Hydroxy-2-{[2-(o- en intravenously for short-term use. Studies with other minute by infusion to a usual maximum total dose (in- methoxyphenoxy)ethyl]amino}ethyl)-o-toluenesulphonamide inotropic phosphodiesterase inhibitors have shown that cluding loading doses) of 10 mg/kg in 24 hours. Doses hydrochloride. their prolonged oral use can increase the mortality rate. of up to 18 mg/kg daily have been used for short peri- Амосулалола Гидрохлорид ◊ References. ods in a limited number of patients. C18H24N2O5S,HCl = 416.9. 1. Wynne J, et al. Oral amrinone in refractory congestive heart fail- Administration in infants. Pharmacokinetic and pharmaco- CAS — 85320-68-9 (amosulalol); 70958-86-0 (amosula- ure. Am J Cardiol 1980; 45: 1245–9. dynamic studies1,2 in infants undergoing cardiac surgery indicat- lol hydrochloride); 93633-92-2 (amosulalol hydrochloride). 2. Wilmshurst PT, Webb-Peploe MM. Side effects of amrinone ed that the dose needed for infants to achieve a plasma-amrinone therapy. Br Heart J 1983; 49: 447–51. concentration of 2 to 7 micrograms/mL was an initial intrave- 3. Wilmshurst PT, et al. The effects of amrinone on platelet count, nous bolus of 3 to 4.5 mg/kg in divided doses followed by a con- survival and function in patients with congestive cardiac failure.
    [Show full text]
  • Summary of Product Characteristics, Labelling and Package Leaflet
    SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Ramipril “Actavis” 1.25 mg, tablets Ramipril “Actavis” 2.5 mg, tablets Ramipril “Actavis” 5 mg, tablets Ramipril “Actavis” 10 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 1.25 mg, 2.5 mg, 5 mg or 10 mg ramipril. Excipient with known effect: One 1.25 mg tablet contains 76 mg of lactose (as lactose monohydrate). Excipient with known effect: One 2.5 mg tablet contains 150 mg of lactose (as lactose monohydrate). Excipient with known effect: One 5 mg tablet contains 92 mg of lactose (as lactose monohydrate). Excipient with known effect: One 10 mg tablet contains 184 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. Ramipril “Actavis” 1.25 mg tablets are white to whitish, capsule-shaped, not coated, flat tablets, 8,0 x 4,0 mm. Ramipril “Actavis” 2.5 mg tablets are yellow, capsule-shaped, not coated, flat tablets, 10,0 x 5,0 mm, scored on one side and on the edges, marked “R2”. The tablets can be divided into equal doses. Ramipril “Actavis” 5 mg tablets are pink, capsule-shaped, not coated, flat tablets, 8,8 x 4,4 mm, scored on one side and on the edges, marked “R3. The tablets can be divided into equal doses. Ramipril “Actavis” 10 mg tablets are white to whitish, capsule-shaped, not coated, flat tablets, 11,0 *5,5 mm, scored on one side and on the edges, marked “R4”.
    [Show full text]